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Abstract
Gouty arthritis is a characteristically intense acute inflammatory
reaction that erupts in response to articular deposits of mono-
sodium urate (MSU) crystals. Important recent molecular biologic
advances in this field have given us a clear picture of the
mechanistic basis of gouty inflammation. The innate immune
inflammatory response is critically involved in the pathology of gout.
Specifically, MSU crystals promote inflammation directly by
stimulating cells via Toll-like receptor signaling and by providing a
surface for cleavage of C5 and formation of complement membrane
attack complex (C5b-9), culminating in secretion of cytokines,
chemokines, and other inflammatory mediators with a dramatic influx
of neutrophils into the joint. Despite the detailed mechanistic picture
for gouty inflammation, there are no placebo-controlled, randomized
clinical studies for any of the therapies commonly used, although
comparative studies have demonstrated that many nonsteroidal
anti-inflammatory drugs are equivalent to indomethacin with respect
to controlling acute gouty attacks. In general, the first line of anti-
inflammatory therapy for acute gout is nonsteroidal anti-inflammatory
drugs, and the selective cyclo-oxygenase-2 inhibitor celecoxib can
be used where appropriate. The second line of treatment is gluco-
corticosteroids, given systemically (oral, intravenous, or intra-
muscular) or intra-articularly. Alternatively, synthetic adrenocortico-
tropic hormone is effective, partly via induction of adrenal
glucocorticosteroids and partly via rapid peripheral suppression of
leukocyte activation by melatonin receptor 3 signaling. The third line
of treatment is oral colchicine, which is highly effective when given
early in an acute gouty attack, but it is poorly tolerated because of
predictable gastrointestinal side effects.
Introduction
Gouty arthritis is a characteristically intense acute inflam-
matory reaction that erupts in response to articular deposits
of monosodium urate (MSU) crystals. Tophi appear to
continually recruit monocytes that differentiate to macro-
phages, and tophi also continually remodel [1], but it is now
appreciated that uptake of MSU crystals by fully differentiated
macrophages potentially exerts anti-inflammatory effects [2].
Important recent molecular biologic advances in this field
have given us a clear picture of the mechanistic basis of how
gouty inflammation is triggered. An innate immune
inflammatory response to the naked crystal surface, which
probably sheds bound surface proteins, including anti-
inflammatory crystal surface-bound apolipoprotein B [3] as
the boundaries of MSU crystal deposits expand and contract,
appears intimately involved in the pathology of gout [4,5]. The
process involves terminal complement membrane attack
complex formation triggered by C5 cleavage on the crystal
surface [6] and the capacity of inert MSU crystals to turn on
resident cells in the joint [7] and to induce generation of IL-8
and related CXC chemokine receptor-2 ligands [6,7].
As shown in Figure 1, recognition of the naked MSU crystal
by Toll-like receptor (TLR)2 and TLR4, which are normally
involved in triggering innate host defense responses to
infectious pathogens, was recently discovered to be a
primary trigger of the inflammatory and degenerative tissue
reactions associated with gouty arthritis [4,5]. TLR2, TLR4,
and the TLR adaptor protein MyD88 promote ingestion of the
naked MSU crystal by phagocytes [5]. Furthermore,
downstream of recognition by TLR2 and TLR4 of the MSU
crystal, MyD88, Rac1, phosphatidylinositol-3 kinase, and Akt
signaling transduce activation of the transcription factor
nuclear factor-κB and expression of a variety of pro-
inflammatory molecules [4,5]. As also shown in Figure 1,
intracellular assembly of the cytosolic NACHT-LRR-PYD-
containing protein (NALP)3 (cryopyrin) inflammasome protein
complex is subsequently triggered by ingested MSU crystals
in phagocytes [8]. The inflammasome assembly in response
to MSU crystals triggers caspase-1 activation and the
maturation and release of IL-1β in phagocytes, and the MSU
crystal-induced NALP3 inflammasome protein complex
assembly is suppressed by the microtubule inhibitor
colchicine [8]. Other events linked to ‘early induced innate
immune response’ in gouty inflammation include expression
on infiltrating phagocytes of the ‘triggering receptor
expressed on myeloid cells’ 1 (TREM-1) [9,10].
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The primary pathologic hallmark of gout is neutrophil influx into
the joint fluid [3], which is consistent with IL-1 and tumor
necrosis factor-α-induced activation of endothelium with
resulting expression of adhesion molecules for leukocytes
[11,12]. Neutrophils accumulate in both the joint fluid and the
synovial membrane, where a small fraction of these cells
actively phagocytose MSU crystals and release mediators.
These mediators include the abundant neutrophil cytosolic
proteins S100A8/S100A9 (formerly termed ‘crystal-induced
chemotactic factor’ [CCF]) [13,14], which are low-molecular-
weight mediators, such as prostanoids and leukotrienes, that
are chemotactic and amplify the inflammatory reaction. The
model for the innate immune inflammatory response that drives
the acute gouty attack was recently reviewed in detail [10].
Acute gouty attacks are by nature self limiting. Multiple
mechanisms have been proposed for the spontaneous
resolution of acute gout, including coating of crystals with
protective proteins and changes in the balance of expression
of proinflammatory and anti-inflammatory factors as the cell
population within the inflamed joint changes [3]. The influx of
monocytes that follows on the heels of neutrophil influx in
acute gout appears significant. As monocytes mature to
macrophages, their response to MSU crystals changes from
proinflammatory [15] to anti-inflammatory. Specifically, fully
differentiated macrophages that ingest MSU crystals can
release transforming growth factor-β1, a potent anti-
inflammatory cytokine for MSU crystal-induced inflammation
[16], which constitutes an anti-inflammatory crystal disposal
mechanism [2,17,18]. Macrophage uptake of apoptotic
neutrophils is also likely to be central to spontaneous
resolution of gouty inflammation, again partly via release of
transforming growth factor-β1 [19].
Essentially, innate immune ‘early induced’ responses do not
directly induce immunologic memory or durable protective
immunity [10]. The stereotypic response in acute gout is
consistent with the recurrent paroxysmal nature of the disease
and the primary role in pathogenesis of ‘professional
phagocytes’, unlike the case for inflammation driven by
adaptive immune responses [10]. The breaching of tissue
barriers by the MSU crystal can stimulate innate immune
alternative complement pathway activation, expression of
chemokines and certain other inflammatory cytokines, and
uptake of the crystal by resident and recruited ‘professional
phagocytes’ in a rapid effort to eliminate the noxious agent. It
is remarkable that gout, the most ancient rheumatic disease, is
driven by the most primitive form of the immune response [10].
Current pharmacologic options for acute
gouty inflammation
Given the aforementioned mechanisms involved in triggering
acute gout, anti-inflammatory agents are naturally the primary
modality for treating acute attacks of gout, using the major
options listed in Table 1. Nonsteroidal anti-inflammatory drugs
(NSAIDs) such as indomethacin and naproxen are frequently
used as first-line therapies for acute gout; however, these
agents may have serious side effects such as gastrointestinal
toxicity, renal toxicity, or gastrointestinal bleeding. Systemic
corticosteroids have also exhibited significant efficacy in
patients with acute gout; intra-articular corticosteroids are
frequently used in patients with monarticular gout, particularly
in patients who cannot receive oral therapy. Parenteral
adrenocorticotropic hormone (ACTH) is also quite useful in
treating acute gout, particularly in those patients with renal
and/or gastrointestinal contraindications to other therapies.
Synthetic ACTH is effective partly via induction of adrenal
glucocorticosteroids, and partly via rapid peripheral
suppression of leukocyte activation by melatonin receptor 3
signaling [20]. In patients with contraindications or who
cannot tolerate NSAIDs or systemic (either oral or parenteral)
corticosteroids, oral colchicine is generally the next choice for
primary therapy. As the acute attack resolves it is appropriate
to use low doses of oral colchicine as an adjunct to NSAID,
glucocorticosteroid, or ACTH treatment, and continuation of
low dose oral colchicine can help to suppress rebound flares
after such treatment.
Figure 1
The innate immune response in recognition, uptake, and responses of
cells to monosodium urate (MSU) crystals. As discussed in the text,
recognition of the naked MSU crystal by the toll-like receptors 2 and 4
(TLR2, TLR4), which are normally involved in triggering innate host
defense responses to infectious pathogens is a primary trigger of
inflammatory and degenerative tissue reactions associated with gouty
arthritis. TLR2, TLR4, and the TLR adaptor protein MyD88 promote
ingestion of the naked MSU crystal by phagocytes. Downstream of
TLR2 and TLR4 recognition of the MSU crystal, MyD88 transduces
activation of the transcription factor NF-κB and the expression of a
variety of pro-inflammatory mediators. Intracellular assembly of the
cytosolic NALP3 (cryopyrin) inflammasome protein complex is
subsequently triggered by delivery to the inflamamsome of ingested
MSU crystals in phagocytes. The inflammasome assembly in response
to MSU crystals triggers caspase-1 activation and the maturation and
release of IL-1β in phagocytes. MSU crystal-induced (but not ATP-
induced) NALP3 inflammasome protein complex assembly is
suppressed by high concentrations of the microtubule inhibitor
colchicine, suggesting that a high concentration of colchicine blocks
delivery of the crystals to the NALP3 inflammasome AP, activator
protein; iNOS, inducible nitric oxide synthase; MMP, matrix
metalloproteinase.
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Only a single trial, conducted by Bellamy and colleagues
[21], has examined the natural course of acute gout; in the
absence of adequate placebo-controlled studies, this trial
serves as a benchmark for comparing the efficacy of other
treatments. In this 7-day study, two out of 11 patients
withdrew because of severe persistent pain after 4 days. All
of the remaining patients showed some improvement in pain
by day 5 and in swelling by day 7. Tenderness improved in
seven of the nine remaining patients; however, full resolution
of pain was observed in only three patients.
Available online http://arthritis-research.com/content/8/S1/S3
Table 1
Recommended treatment options for acute gouty arthritis
Drug Example regimens Major considerations
NSAIDs (selected agents; no study has shown differences among NSAIDs in efficacy)
Naproxen 750–1000 mg orally for 3 days followed by There may be cost savings relative to other treatments for 
500–750 mg orally daily for 4–7 days acute attacks
Should be avoided in patients with renal or hepatic failure and 
Sulindac 300–400 mg orally for 7–10 days patients at risk for clinically significant gastrointestinal events 
Consider co-administration of PPI in patients at risk for clinically 
Indomethacin 150–200 mg orally for 3 days followed by significant gastrointestinal events
100 mg orally daily for 4–7 days
COX-2 inhibitors
Celecoxib 400 mg orally on the first day, then May provide better gastrointestinal tolerability than NSAIDs 
200 mg/day (in two divided doses) for Gastrointestinal protective effect lost in patients taking 
6–10 days concomitant aspirin 
Potential risk for cardiovascular adverse events, including 
hypertension
Systemic corticosteroids
Prednisone 40–60 mg/day for 3 days, then decrease Avoid use if joint sepsis not excluded 
by 10–15 mg/day every 3 days until Avoid in patients subject to hyperglycemia
discontinuation
Methylprednisolone 100–150 mg per day for 1–2 days
Triamcinolone acetonide 60 mg intramuscularly once
Intra-articular corticosteroids
Triamcinolone acetonide 10 mg in knees and 8 mg in small Only useful in patients with one or a few affected joints 
joints intra-articularly once Avoid use if joint sepsis is not excluded
ACTH
25 USP units subcutaneously for acute Not universally available 
small-joint monoarticular gout; 40 USP units Less effective in patients receiving long-term oral corticosteroid 
intramuscularly or intravenously for larger therapy 
joints or polyarticular gout Risk for corticotrophin hypersensitivity (less frequent with 
synthetic formulation)
Colchicine (oral)
For acute episodes within the first 24 hours Avoid or reduce dose in elderly or frail patients or those with 
in patients not already on prophylactic renal or hepatic dysfunction 
low-dose colchicine: 0.6 mg initially followed All patients who receive therapeutic dosages of colchicine will 
by additional doses of 0.6 mg every hour develop toxic effects 
(typically for a total of three to four doses, but Potential drug interactions with erythromycin, simvastatin, and 
to a maximum of eight doses because more cyclosporine; may increase risk for colchicine-induced toxic 
prolonged dosing often causes significant effects 
diarrhea, which can be accompanied by nausea Avoid intravenous colchicines
and vomiting and may be severe enough to 
promote dehydration). This regimen can be 
used as an adjunct to other modalities and is 
typically followed by a daily low-dose oral 
colchicine regimen to prevent rebound
Adapted with modifications from Terkeltaub RA [42]. ACTH, adrenocorticotropic hormone; COX, cyclo-oxygenase; NSAID, nonsteroidal anti-
inflammatory drug; PPI, proton pump inhibitor.
Few randomized controlled trials have been conducted to
evaluate the efficacy of the various treatments for acute gouty
arthritis. The data summarized below are – except where
noted otherwise – from small, uncontrolled studies that were
conducted in relatively heterogeneous patient populations.
There remains a need for prospective evaluation of the
efficacy and safety of treatments for acute gout.
Nonsteroidal anti-inflammatory drugs
Data suggest that generic NSAIDs can provide marked
symptomatic relief within 24 hours of administration and may
also provide substantial cost savings over other treatments
for acute gout. NSAIDs have therefore become the drug of
first choice in patients with acute attacks of gout who do not
have underlying contraindications against their use.
Head-to-head studies of NSAIDs in patients with acute gouty
arthritis suggest that there are few differences among these
agents in terms of efficacy [22-24]. In an early study
conducted by Smyth and Percy [25], indomethacin and
phenylbutazone were compared in 28 patients (31 attacks).
In this study, complete subjective relief from pain was
obtained in a median of 5 days with both agents; the results
for other outcome measures, including rest pain, tenderness,
heat, erythema, swelling, and number of recurrences, were
largely similar in the two treatment groups. In a second study,
conducted by Altman and colleagues [26], 59 patients
received double-blind treatment with ketoprofen 100 mg
(n = 29) or indomethacin 50 mg (n = 30) three times a day. In
both groups more than 90% of patients reported pain relief
within the first day of treatment. After 5 days of treatment,
seven ketoprofen patients and six indomethacin patients
discontinued treatment because of complete or substantial
pain relief. The majority of patients in both groups were rated
as having marked improvement both by the investigators and
by self-assessment.
The gastrointestinal adverse effects of traditional NSAIDs are
well known. Clinically important NSAID-related events, such
as gastrointestinal bleeding, result in more than 100,000
hospitalizations and 16,500 deaths each year in the USA
alone. Endoscopic studies indicate that gastric or duodenal
ulcers develop in between 15% and 30% of patients who
regularly take these agents [27]. Other adverse effects of
NSAIDs include reduced creatinine clearance, hyperkalemia,
and elevations in liver enzymes. Elderly patients, those with
established gastrointestinal disease, and those with impaired
renal function are at greatest risk for NSAID-associated
adverse effects [28]. The gastrointestinal side effects of
NSAIDs may, in part, be lessened by co-administration of a
proton pump inhibitor.
Together, these data indicate that the traditional NSAIDs are
effective in the treatment of acute gout; however, the useful-
ness of NSAIDs is limited by their side effects, particularly
given that patients with acute gout are likely to receive
relatively high dosages of these medications. Cyclo-
oxygenase (COX)-2-specific inhibition may be useful in
patients with acute gout, particularly those with established
gastrointestinal disease or others who cannot tolerate the
gastrointestinal adverse effects of traditional NSAIDs.
The efficacy of etoricoxib, a COX-2 inhibitor, was compared
with that of indomethacin in 142 men and 8 women with
acute gout [29]. Patients received etoricoxib 120 mg/day or
indomethacin 50 mg three times a day for 8 days; therapy
was initiated within 48 hours of symptom onset. The primary
outcome measures of this study were patient assessment of
pain in the affected joint over days 2–5 and investigator-
assessed and patient-assessed pain and tenderness in the
inflamed joint on a 0- to 4-point Likert scale. The efficacy of
etoricoxib was similar to that of indomethacin for all efficacy
end-points; however, drug-related adverse events were
significantly less frequent among patients who received
etoricoxib (22.7%) than among those who received
indomethacin (46.7%).
These data suggest that COX-2 inhibitors – of which only
celecoxib is available at the time of writing – are effective in
treating acute gouty arthritis and may be associated with
fewer adverse effects than traditional NSAIDs, at least in
short-term treatment. Recently, concerns have been raised
regarding the relationship between COX-2 inhibitors and
cardiovascular adverse events; these concerns may limit the
applicability of these agents in the prophylactic setting.
Corticosteroids
Systemic corticosteroids have been used for the treatment of
acute gout since 1952. As with other treatments for gout,
systematic studies of the efficacy of corticosteroids – both
systemic therapy and intra-articular therapy – are lacking.
However, at least at relatively large doses, systemic cortico-
steroid therapy appears to be associated with good
responses and few important side effects.
In a study conducted by Groff and colleagues [30], patients
with acute gout who had contraindications to NSAIDs
received short-term therapy with systemic corticosteroids.
Patients were treated with prednisone at dosages ranging
from 20 to 50 mg/day, with a tapering schedule over a mean
of 10.5 days (n = 9); three more difficult-to-manage patients
received initial intravenous therapy with prednisolone or
prolonged prednisone over 17 days. All patients except one
noted improvement within 48 hours; complete resolution of
the signs and symptoms of acute gout occurred within 7 days
in 11 out of 13 episodes and within 10 days in the remainder.
A systematic comparison of different systemic corticosteroid
dosing regimens has not yet been conducted in patients with
acute gout.
In a second study, reported by Alloway and colleagues [31],
27 patients with proven acute gout received indomethacin
Arthritis Research & Therapy    Vol 8 Suppl 1 Cronstein and Terkeltaub
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50 mg three times daily or intramuscular triamcinolone
acetonide 60 mg. Patients were followed for 30 days. The
mean time to symptom resolution was 8 days among patients
who received indomethacin and 7 days among those who
received triamcinolone acetonide. Triamcinolone acetonide
was not associated with rebound gout attacks or clinically
important side effects.
A third study, conducted by Werlen and colleagues [32],
evaluated the efficacy and safety of a single injection of intra-
muscular betamethasone (7 mg), intravenous methylpredniso-
lone (125 mg), or diclofenac 50 mg three times daily for
3 days followed by 25 mg three times daily for an additional
3 days. Efficacy was evaluated by the treating physician after
1, 3, and 6 days based on the subjective global impression of
outcomes and on a 4-point joint swelling scale. Among all
patients enrolled in the study, more than 50% improvement
was observed in 21 out of 25 patients after 24 hours of
therapy. Among patients who received oral diclofenac, more
than 50% improvement was observed in six out of nine
patients; among patients who received intramuscular beta-
methasone or intravenous methylprednisolone, more than 50%
improvement was observed in nine out of 10 and six out of six
patients, respectively, 24 hours after therapy. Further improve-
ments were observed in 23 out of 25 patients after 3 days.
Overall, subjective improvement was more than 90% in 19 out
of 25 patients after 6 days. No adverse effects were observed
among patients who received diclofenac; among patients who
received betamethasone one patient with established diarrhea
developed hyperglycemia and one patient who received
methylprednisolone developed hot flushes.
Intra-articular injections of corticosteroids are useful in cases
involving one or few joints. The value of intra-articular cortico-
steroids is supported by the results of several small, open-
label studies. Patients with polyarticular gout may benefit from
intra-articular treatment of joints with persistent synovitis [33].
In a small case series reported by Fernandez and colleagues
[34], 19 men (20 attacks) received triamcinolone acetonide
(10 mg in knees and 8 mg in small joints). At this relatively
low dosage, attacks were resolved in 11 joints (55%) at
24 hours and in nine joints (45%) at 48 hours. All attacks
were fully resolved 48 hours after treatment.
Synthetic adrenocorticotropic hormone
Parenteral ACTH is useful in acute gout, particularly in
patients with renal and/or gastrointestinal contraindications to
other therapies. The efficacy of ACTH in treating episodes of
acute gout was retrospectively examined in a study
conducted by Ritter and colleagues [35]. A total of 38
patients with acute gout and five patients with acute pseudo-
gout with indications for ACTH therapy (including congestive
heart failure, chronic renal insufficiency, gastrointestinal
bleeding, or lack of response to an NSAID) received ACTH
treatment. Patients received intravenous (n = 27), intra-
muscular (n = 6), or subcutaneous (n = 5) drug, most
commonly at 40 IU every 8 hours followed by 40 IU every
12 hours and then 40 IU once daily; the duration of therapy
ranged from 1 day to 12 days. Seventy-nine per cent of
patients received prophylactic colchicine as the ACTH dose
was tapered. All episodes of pseudogout resolved in a mean
of 4.2 days; 97% of acute gout episodes resolved in an
average of 5.5 days. There were three episodes of relapse
despite the use of prophylactic colchicine and one relapse in
a patient who did not receive colchicine. Mild hypokalemia,
hyperglycemia, edema, and rebound arthritis occurred among
patients receiving ACTH; however, all were controlled easily.
The efficacies of indomethacin and ACTH were compared in
a prospective, quasi-randomized study conducted by Axelrod
and Preston [36]. In this study, 100 male patients who
presented with acute gouty arthritis (confirmed by crystal
diagnosis) were alternately assigned to therapy with single
intramuscular injection of ACTH (40 IU) or oral indomethacin
(50 mg, four times daily) until pain abated. Each gout attack
during a 1-year period was treated; during each treatment
course patients were treated and observed for 5 hours before
release. Seventy-six patients completed the study protocol; in
these patients, the mean interval to relief from pain was
significantly shorter among those assigned to ACTH
(3 hours) than among those who received indomethacin
(24 hours). Pain resolved within 4 hours. No adverse effects
were observed among patients who received intramuscular
ACTH. In contrast, a broad range of side effects – including
gastrointestinal and neurologic adverse events – were
observed among patients who received indomethacin.
A single prospective, randomized controlled trial of ACTH has
been conducted. In this study, conducted by Siegel and
colleagues [37], 31 patients with acute gout received either a
single dose of intramuscular ACTH (40 IU; n = 16) or tri-
amcinolone acetate (60 mg; n = 15). The time to complete
resolution of symptoms was similar in the two groups (7.9
and 7.6 days, respectively). Patients who received triamcino-
lone acetate required fewer repeat injections compared with
the ACTH group.
It is surprising that so few systematic studies on the best
treatment of acute gouty arthritis have been carried out.
Nonetheless, the literature does indicate that a number of
efficacious therapies are available. The optimal therapy for
any given patient should be tailored to that individual’s needs.
Fortunately, there are numerous options that all appear to be
similarly efficacious. Nonetheless, prospective studies of the
various therapies available for treating gout should be carried
out to determine the best approaches to therapy.
Colchicine
Colchicine, an alkaloid derived from the autumn crocus
Colchicum autumnale, has been used to treat inflammatory
diseases for nearly 2000 years. However, it was not until
Available online http://arthritis-research.com/content/8/S1/S3
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1920 that colchicine, the pharmacologically active derivative
of the plant, was isolated. Colchicine has many pharmaco-
logic effects that may contribute to its anti-inflammatory
actions. The earliest effect to be demonstrated is the capacity
of colchicine to block microtubule assembly in neutrophils
and other inflammatory cells, an effect that leads to
diminished phagocytosis and transport of MSU crystals to the
lysosome [28]. Because of its ability to alter microtubule
assembly, colchicine also alters the expression of a number of
cell surface proteins, including downregulation of tumor
necrosis factor-α receptors, insulin, and β-adrenergic
agonists [38,39]. Colchicine also inhibits the release of
chemotactic factors (including both peptide-derived and lipid-
derived mediators such as leukotriene B4 from neutrophils),
specifically inhibits signaling for activation in neutrophils
exposed to MSU crystals, and reduces adhesion and
recruitment of polymorphonuclear leukocytes to the inflamed
joint via suppression of neutrophil L-selectin expression and
alteration of E-selectin distribution on stimulated endothelial
cells. The recent, compelling demonstration of colchicine
suppression of MSU crystal-induced NALP3 inflammasome-
driven caspase-1 activation and IL-1β processing [8]
illustrates another substantial anti-inflammatory effect of
colchicine. This effect likely occurs via microtubule inhibition,
and impaired delivery of MSU crystals to the NALP3
inflammatory protein complex in the cytosol, and it requires
relatively high (micromolar) concentrations of colchicine [8].
In treating acute gouty arthritis colchicine is typically
administered as an oral 0.6 mg dose, followed by 0.6 mg at
hourly intervals until gastrointestinal side effects (e.g. nausea,
vomiting, or diarrhea) occur or a maximum total of six to eight
doses has been administered. Many patients only require three
to four doses of 0.6 mg oral colchicine to achieve substantial
improvement. Limited dose oral colchcine regimens of this
type, particularly if started within the first 24 hours of the gout
flare, are useful because they can lessen the frequency of
gastrointestinal toxicity, which sometimes is severe. In most
patients, substantial relief is observed by 18 hours and diarrhea
generally develops within 24 hours. Joint inflammation subsides
over 48 hours in more than 75% of patients [28]. Colchicine is
a potentially toxic drug that can result in fatal complications;
indeed, colchicine probably has the smallest therapeutic
window of any drug used to treat acute gouty arthritis.
Intravenous colchicine has fewer gastrointestinal side effects
than oral colchicine, although its primary and most worrisome
complication is bone marrow suppression, which can be lethal.
The effects of oral colchicine in patients with acute gout have
been studied in only one placebo-controlled trial. In this
study, conducted by Ahern and colleagues [40], 43 patients
were randomly assigned to placebo (n = 21) or to colchicine
1 mg followed by 0.5 mg every 2 hours until complete
response or toxicity (n = 22); patients were not allowed to
take NSAIDs during the study period. Approximately two-
thirds of colchicine-treated patients improved after 48 hours,
compared with one-third of patients in the placebo group.
Moreover, colchicine-treated patients responded to treatment
earlier, with significant differences from placebo observed
18–30 hours from baseline. All 22 patients who received
colchicine developed diarrhea after a median of 24 hours
(range 12–36 hours) or after a mean dose of colchicine of
6.7 mg. In most patients, gastrointestinal side effects
occurred before the relief of pain. Because the frequency of
gastrointestinal toxicity with high-dose colchicine is
essentially 100% and newer, less toxic agents are available
for the treatment of acute gouty attacks, this regimen has
fallen into disfavor and is not used often.
An alternative to the use of oral colchicine is intravenous
colchicine. Although there is far less gastrointestinal toxicity
with intravenous colchicine, its use has fallen into disfavor as
a result of substantial systemic toxicities – particularly bone
marrow suppression – and reports of 33 deaths between
1985 and 1997 [41]. These adverse effects may occur even
with low doses of colchicine (< 2 mg) in patients with hepato-
biliary obstruction, renal insufficiency, and/or advanced age
[42]. Extravasation of colchicine out of the vein can cause
tissue necrosis. The use of intravenous colchicine should be
avoided in the treatment of acute gout.
Conclusion
The molecular basis of acute gouty inflammation is well
defined, but there is a lack of evidence from prospectively
designed, randomized clinical trials on the best treatment for
acute gout. Nonetheless, several approaches to the treatment
of acute gouty arthritis appear to be efficacious. Well
designed comparative clinical studies of these treatments are
needed to refine evidence-based treatment decisions in
acute gouty inflammation.
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